Description
The epidermal growth factor receptor (EGFR) is a 170,000-kDa trans-membrane glycoprotein involved in signaling pathways affecting cellular growth, differentiation, and proliferation.1 An abnormal expression of the EGFR has been described in many human tumors and implicated in the development and prognosis of malignancies, thus representing not only a possible prognostic markers but primarily a rational molecular target for a new class of anticancer agents